Zacks Investment Research upgraded shares of Chemours Company (The) (NYSE:CC) from a hold rating to a strong-buy rating in a report released on Tuesday morning. Zacks Investment Research currently has $61.00 price target on the specialty chemicals company’s stock.

According to Zacks, “Chemours Company is involved in chemical business. It operating segment consists of Titanium Technologies, Fluoroproducts and Chemical Solutions. Titanium Technologies segment produces titanium dioxide and premium white pigment. Fluoroproducts segment provides fluoroproducts, refrigerants and industrial fluoropolymer resins. Chemical Solutions segment provides industrial and specialty chemicals. The company’s brand consists of Teflon(R), Ti-Pure(R), Krytox(R) Viton(R), Opteon(R) and Nafion(R). Chemours Company is headquartered in Wilmington. “

A number of other equities research analysts have also commented on CC. BidaskClub cut Chemours Company (The) from a buy rating to a hold rating in a research note on Friday, August 11th. Jefferies Group LLC reaffirmed a buy rating and set a $48.00 price objective on shares of Chemours Company (The) in a report on Friday, June 16th. Citigroup Inc. raised shares of Chemours Company (The) from a neutral rating to a buy rating and lifted their price objective for the stock from $43.00 to $45.00 in a report on Wednesday, July 5th. Argus reiterated a buy rating and issued a $55.00 target price (up previously from $50.00) on shares of Chemours Company (The) in a research note on Thursday, August 10th. Finally, UBS AG upgraded shares of Chemours Company (The) from a sell rating to a neutral rating and upped their target price for the stock from $36.00 to $50.00 in a research note on Monday, August 7th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Chemours Company (The) has a consensus rating of Buy and an average target price of $52.75.

Chemours Company (NYSE:CC) traded down 0.15% on Tuesday, hitting $53.36. 339,072 shares of the stock traded hands. The firm has a market capitalization of $9.86 billion, a PE ratio of 34.92 and a beta of 3.59. Chemours Company has a 52 week low of $14.41 and a 52 week high of $53.65. The stock has a 50 day moving average of $51.00 and a 200 day moving average of $51.00.

Chemours Company (The) (NYSE:CC) last announced its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.02. The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. Chemours Company (The)’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.27 earnings per share. Equities research analysts anticipate that Chemours Company will post $3.51 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Chemours Company (The) (CC) Upgraded to “Strong-Buy” by Zacks Investment Research” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/10/04/chemours-company-the-cc-upgraded-to-strong-buy-by-zacks-investment-research.html.

The firm also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 17th were issued a dividend of $0.03 per share. The ex-dividend date was Tuesday, August 15th. This represents a $0.12 dividend on an annualized basis and a yield of 0.22%. Chemours Company (The)’s dividend payout ratio (DPR) is currently 8.11%.

In other news, VP Amy Trojanowski sold 2,500 shares of the firm’s stock in a transaction on Friday, August 11th. The stock was sold at an average price of $46.03, for a total transaction of $115,075.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider E Bryan Snell sold 10,000 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.24, for a total value of $462,400.00. The disclosure for this sale can be found here. In the last three months, insiders sold 38,837 shares of company stock worth $1,865,603. Insiders own 1.14% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CC. BlackRock Inc. boosted its holdings in shares of Chemours Company (The) by 48,297.2% in the 1st quarter. BlackRock Inc. now owns 19,160,930 shares of the specialty chemicals company’s stock worth $737,696,000 after buying an additional 19,121,339 shares during the last quarter. Vanguard Group Inc. grew its position in Chemours Company (The) by 1.2% during the first quarter. Vanguard Group Inc. now owns 18,773,273 shares of the specialty chemicals company’s stock valued at $722,771,000 after buying an additional 215,900 shares during the period. FMR LLC grew its position in Chemours Company (The) by 6.1% during the second quarter. FMR LLC now owns 15,830,411 shares of the specialty chemicals company’s stock valued at $600,289,000 after buying an additional 905,038 shares during the period. State Street Corp grew its position in Chemours Company (The) by 35.1% during the first quarter. State Street Corp now owns 5,791,792 shares of the specialty chemicals company’s stock valued at $222,987,000 after buying an additional 1,504,657 shares during the period. Finally, Renaissance Technologies LLC grew its position in Chemours Company (The) by 10.3% during the second quarter. Renaissance Technologies LLC now owns 3,342,200 shares of the specialty chemicals company’s stock valued at $126,736,000 after buying an additional 310,800 shares during the period. Institutional investors own 72.90% of the company’s stock.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Analyst Recommendations for Chemours Company (The) (NYSE:CC)

Receive News & Stock Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related stocks with our FREE daily email newsletter.